| Full text | |
| Author(s): |
Zamorano, Mauricio
[1]
;
Castillo, Rodrigo L.
[2]
;
Beltran, Jorge F.
[1]
;
Herrera, Lisandra
[1]
;
Farias, Joaquin A.
[3]
;
Antileo, Christian
[1]
;
Aguilar-Gallardo, Cristobal
[4]
;
Pessoa, Adalberto
[5]
;
Calle, Yolanda
[6]
;
Farias, Jorge G.
[1]
Total Authors: 10
|
| Affiliation: | [1] Univ La Frontera, Dept Chem Engn, Temuco - Chile
[2] Univ Chile, Dept Internal Med, Santiago - Chile
[3] Univ Adolfo Ibintez, Fac Ingn & Ciencias, Santiago - Chile
[4] Hosp Univ & Politecn La Fe, Hematol Transplant & Cell Therapy Unit, Valencia - Spain
[5] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Biochem & Pharmaceut Technol, Sao Paulo - Brazil
[6] Univ Roehampton, Whitelands Coll, Dept Life Sci, London - England
Total Affiliations: 6
|
| Document type: | Review article |
| Source: | FRONTIERS IN PHYSIOLOGY; v. 12, SEP 17 2021. |
| Web of Science Citations: | 0 |
| Abstract | |
Ischemia is a severe condition in which blood supply, including oxygen (O), to organs and tissues is interrupted and reduced. This is usually due to a clog or blockage in the arteries that feed the affected organ. Reinstatement of blood flow is essential to salvage ischemic tissues, restoring O, and nutrient supply. However, reperfusion itself may lead to major adverse consequences. Ischemia-reperfusion injury is often prompted by the local and systemic inflammatory reaction, as well as oxidative stress, and contributes to organ and tissue damage. In addition, the duration and consecutive ischemia-reperfusion cycles are related to the severity of the damage and could lead to chronic wounds. Clinical pathophysiological conditions associated with reperfusion events, including stroke, myocardial infarction, wounds, lung, renal, liver, and intestinal damage or failure, are concomitant in due process with a disability, morbidity, and mortality. Consequently, preventive or palliative therapies for this injury are in demand. Tissue engineering offers a promising toolset to tackle ischemia-reperfusion injuries. It devises tissue-mimetics by using the following: (1) the unique therapeutic features of stem cells, i.e., self-renewal, differentiability, anti-inflammatory, and immunosuppressants effects; (2) growth factors to drive cell growth, and development; (3) functional biomaterials, to provide defined microarchitecture for cell-cell interactions; (4) bioprocess design tools to emulate the macroscopic environment that interacts with tissues. This strategy allows the production of cell therapeutics capable of addressing ischemia-reperfusion injury (IRI). In addition, it allows the development of physiological-tissue-mimetics to study this condition or to assess the effect of drugs. Thus, it provides a sound platform for a better understanding of the reperfusion condition. This review article presents a synopsis and discusses tissue engineering applications available to treat various types of ischemia-reperfusions, ultimately aiming to highlight possible therapies and to bring closer the gap between preclinical and clinical settings.</p> (AU) | |
| FAPESP's process: | 20/06982-3 - Chimeric and pegylated L-asparaginase: study of the conditions of expression, production and purification of an innovative anti-leukemic biopharmaceutical with low immunogenic potential |
| Grantee: | Adalberto Pessoa Junior |
| Support Opportunities: | Regular Research Grants |